Features May 2010 Issue

A Potent Alternative to Clopidogrel Emerges

Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.

Clopidogrel (Plavix) is one of the best-selling drugs in the world and is a proven treatment to help reduce the risk of blood clot formation in patients with coronary artery disease, peripheral vascular disease and cerebrovascular disease. However, about 25 percent of the patients who are prescribed clopidogrel donít respond well to it, explains Stephen G. Ellis, MD, Section Head of Invasive/Interventional Cardiology in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.